Background: Associated cerebral vascular lesions (CvaLs) are frequent and confers greater severity to PD. Study objective - determining association and impact of CVaLs on PD in Moldovan cohort (part of national project 20.80009.8007.39) Methods: These are preliminary data of 111 consecutive PDp from a national tertiary center, mean age 64.87 ± 7.69 y.o., mean disease duration 50.21 ± 38.61 months, 48 women (43.2%) and 63 (56.8%) men. Clinical evaluation and brain MRI 3T were performed. Presence of: white matter lesions, lacunas, deepening of cerebral fissures, widening of the ventricles and of the perivascular spaces was visually rated. Volumetry of CVaLs - in process. Results: CVaLs were found in 78.4% of all cases; in 75.3% of definite and 77% of probable PDp; also in 90% cases of predominantly lower body parkinsonism. Normal cognition patients had CVaLs in 83%, MCI patients – 76.5%, mild dementia patients – 75.0%, and moderate dementia patients – 100% of cases (there were no severely demented patients so far). Patients with CVaLs exhibited a significantly higher: number of vascular risk factors (2.83 ± 1.38 vs. 1.73 ± 1.19, p = 0.013), QRISK3 scores (19.68 ± 16.15 vs. 12.9 ± 6.58, p = 0.015), relative risk (5.48 ± 13.45 vs. 1.70 ± 0.39, p = 0.009), and levodopa equivalent daily dose (639.98 ± 223.04 vs. 439.69 ± 224.87, p = 0.048). The UPDRS scores (UPDRSoff 47.26 ± 13.21 vs. 44.13 vs. 8.20; UPDRSon 35.49 ± 11.8 vs. 29.89 vs. 8.99) and Beck scores (7.26 ± 5.62 vs. 6.86 vs. 4.37) were higher; and MoCA scores (21.93 ± 4.25 vs. 22.38 vs. 4.56) lower than in control, thus not reaching the statistical significance. Conclusions: Patients with PD and CVaLs have more cardiovascular risk factors, thus a higher QRISK3 scores and relative risk. They are more severely affected and require higher doses of dopaminergic drugs; have more depression and cognitive impairment.